SEC Form 8-K Summary
Filing date: September 28, 2022. The provided filing identifies the registrant as Jupiter Wellness, Inc., not BONK, Inc. The filing is a Regulation FD disclosure and does not report quarterly or annual financial results.
Business Context and Reporting Period
Jupiter Wellness announced that the U.S. Patent and Trademark Office granted a notice of allowance for patent application No. 16/747,685, titled “Minoxidil Adjuvant Therapies.” The filing covers an event occurring on September 28, 2022.
Financial and Operating Metrics
- Revenue, net income, operating margins, cash flow, debt, liquidity, and balance-sheet metrics are not provided.
- No financial statements or comparable-period financial data are included in the filing text.
Material Changes Versus Prior Period
The filing does not provide prior-period information or quantify any financial or operating changes. The principal disclosed development is the USPTO notice of allowance for the patent application.
Guidance, Outlook, Risks, and Unusual Items
- No formal financial guidance or forecast is provided.
- The patent notice of allowance may support the company’s intellectual-property position, but the filing does not state when a patent will issue or quantify any expected commercial benefit.
- The filing does not describe material contingencies, litigation, financing activity, or other unusual items.
- The furnished press release is identified as Exhibit 99.1, but its substantive text is not included in the provided filing content.
Key Facts for Investor Verification
- Confirm the issuer identity: the source filing names Jupiter Wellness, Inc., with trading symbols JUPW and JUPWW.
- Review Exhibit 99.1 for the complete description of the patent notice, claims, and expected development or commercialization plans.
- Verify whether and when the USPTO issues the patent following the notice of allowance.
- Assess whether the intellectual property has any disclosed impact on revenue prospects, valuation, or competitive position.